Avelumab in Metastatic or Locally Advanced Solid Tumors (JAVELIN Solid Tumor JPN)

Clinical Trial ID NCT01943461

Rank	Title	Journal	Year	PubWeight™‹?›
1	The Next Immune-Checkpoint Inhibitors: PD-1/PD-L1 Blockade in Melanoma.	Clin Ther	2015	1.73
2	Immunotherapy in the treatment of non-small cell lung cancer.	Lung Cancer	2014	1.35
3	Intratumoral immunization: a new paradigm for cancer therapy.	Clin Cancer Res	2014	1.24
4	Trial Watch: Immunostimulatory monoclonal antibodies in cancer therapy.	Oncoimmunology	2014	1.22
5	Cancer immunotherapy in clinical practice -- the past, present, and future.	Chin J Cancer	2014	0.98
6	Immunotherapy for advanced gastric and esophageal cancer: preclinical rationale and ongoing clinical investigations.	J Gastrointest Oncol	2015	0.89
7	The promise of PD-1 inhibitors in gastro-esophageal cancers: microsatellite instability vs. PD-L1.	J Gastrointest Oncol	2016	0.83
8	Current and emerging therapies in unresectable and recurrent gastric cancer.	World J Gastroenterol	2016	0.81
9	The emerging role of immunotherapy in colorectal cancer.	Ann Transl Med	2016	0.80
10	PD-1 and PD-L1 antibodies for melanoma.	Hum Vaccin Immunother	2014	0.80
11	Emerging therapeutic targets in metastatic progression: A focus on breast cancer.	Pharmacol Ther	2016	0.79
12	Immune checkpoint blockade therapy for bladder cancer treatment.	Investig Clin Urol	2016	0.78
13	Immune Checkpoint Modulation in Colorectal Cancer: What's New and What to Expect.	J Immunol Res	2015	0.78